GTS Securities’s Outlook Therapeutics OTLK Stock Holding History

GTS Securities’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-533	Closed	-$2.35K	–	4306
2023 Q3	$2.35K	Buy	+533	New	+$11.8K	﹤0.01%	3847

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GTS Securities's OTLK Position: Q4 2023 in Review

GTS Securities sold out of Outlook Therapeutics (OTLK) in Q4 2023, closing a stake of 533 shares — an estimated $2.35K sold.

GTS Securities first reported a position in OTLK in Q3 2023 and held it in 1 quarter. The position peaked at $2.35K in Q3 2023. 87 funds tracked by Wall St. Rank hold OTLK as of Q4 2023.

GTS Securities reported no remaining Outlook Therapeutics position as of Q4 2023 after selling out during the quarter.
GTS Securities sold 533 Outlook Therapeutics shares in Q4 2023, an estimated $2.35K.
GTS Securities first reported a position in Outlook Therapeutics in Q3 2023 and held it in 1 quarter.
GTS Securities's Outlook Therapeutics position peaked at $2.35K in Q3 2023.
87 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2023.

Based on GTS Securities's 13F filing for Q4 2023, filed 15 Feb 2024.